ELI LILLY & (LLY) Company Report

Lilly will share full data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) at the 67th ASH Annual Meeting, Dec. 6–9 in Orlando.
The BRUIN CLL-314 trial, the first head-to-head Phase 3 comparing non-covalent pirtobrutinib to covalent ibrutinib in treatment-naïve CLL/SLL, met its primary non-inferiority endpoint with a nominal P-value < 0.05 favoring pirtobrutinib.
The BRUIN CLL-313 study versus chemoimmunotherapy in treatment-naïve CLL/SLL (without del(17p)) demonstrated a highly significant and clinically meaningful improvement in progression-free survival with pirtobrutinib.
Additional oral and poster presentations will cover long-term follow-up from the Phase 1/2 BRUIN study in relapsed/refractory CLL, mantle cell lymphoma, Waldenström macroglobulinemia, and investigator-initiated combination regimens.

4 days ago

Press Release

Eli Lilly and Novo Nordisk launch direct-to-employer obesity drug model

LLY

New Projects/Investments

Starting January 1, 2026, Novo Nordisk and Eli Lilly will sell FDA-approved weight loss drugs such as Wegovy and Zepbound directly to self-insured and large employers, bypassing PBMs at fixed upfront prices to reduce costs and improve transparency.
The program, powered by Waltz Health’s AI-driven platform (acquired by EVERSANA in August 2025), provides real-time eligibility screening, prescription routing, adherence monitoring, and an integrated telehealth option for seamless access and clinical safeguards.
Eli Lilly’s approach includes flexible benefit design, a dedicated pharmacy network for enhanced cost tracking, and collaborations with third parties to deliver holistic weight management solutions.
Both companies aim to eliminate unapproved compounded versions of their GLP-1 obesity drugs and help employers tailor benefits, targeting a market projected to reach $150 billion annually by the early 2030s.

7 days ago

Bloomberg

Eli Lilly reaches $1 trillion market capitalization

LLY

Guidance Update

Eli Lilly became the first pharmaceutical company to reach a $1 trillion market cap, driven by its booming weight-loss drug franchise.
The stock surged nearly 70% since early August 2025, peaking at $1,060.90 before settling back.
Management has raised its 2025 financial outlook multiple times, signaling confidence in its expanding portfolio.
Lilly and Novo Nordisk plan to sell their weight-loss drugs directly to employers, aiming to widen access and secure long-term demand.

Nov 20, 2025, 10:08 PM

WSJ

SEED Therapeutics receives NMPA IND clearance for ST-01156

LLY

New Projects/Investments

China’s NMPA cleared the IND for ST-01156, enabling inclusion of Chinese clinical sites in SEED’s planned global expansion study
ST-01156 is SEED’s first clinical candidate, with FDA Orphan Drug and Rare Pediatric Disease designations for Ewing sarcoma
Preclinical data showed complete tumor regression in xenograft models and strong RBM39 target engagement, supporting expansion into RBM39-dependent cancers

Nov 12, 2025, 12:00 PM

Press Release

Eli Lilly shares surge on analyst upgrade and Medicare obesity deal

LLY

Revenue Acceleration/Inflection

Debt Issuance

Product Launch

Leerink Partners upgraded Eli Lilly to Outperform, raising its price target to $1,104, driven by obesity treatment adoption and expanded Medicare/Medicaid access starting 2027.
New pricing agreement expands the pool of eligible Medicare obesity treatment patients from 8.5 million to 40 million, significantly boosting market potential.
Q3 revenue reached $17.60 billion (53.9% y/y) with EPS of $7.02, and the balance sheet shows a current ratio of 1.55 and debt-to-equity of 1.79, following $25.4 billion of new debt over three years.
Upcoming obesity drugs include orforglipron in 2027 and eloralintide in 2028, the latter delivering 16.4% weight loss at 48 weeks in Phase 2 trials and projected for $10.7 billion in risk-adjusted sales.
Analysts project a 15% revenue CAGR and 20% EPS CAGR through 2030 for Eli Lilly.

Nov 10, 2025, 1:46 PM

Morningstar

Eli Lilly enters $75M ophthalmology collaboration with MeiraGTx

LLY

New Projects/Investments

$75 million upfront, plus potential milestone payments exceeding $400 million and tiered royalties, for exclusive global rights to MeiraGTx’s AAV-AIPL1 gene therapy targeting Leber congenital amaurosis 4.
MeiraGTx shares rose 15–18% in premarket trading on the news.
MeiraGTx’s financials highlight a –416.49% operating margin, –415.39% net margin, current and quick ratios of 0.88, and an Altman Z-Score of –5.66.
The deal reinforces MeiraGTx’s leadership in genetic medicine and advances Eli Lilly’s ophthalmology portfolio.

Nov 10, 2025, 12:36 PM

Morningstar

Eli Lilly's Eloralintide Delivers Up to 20% Weight Loss in Phase 2 Trial

LLY

New Projects/Investments

Eloralintide induced up to 20.1% body weight reduction over 48 weeks, with the highest 9 mg dose yielding an average weight loss of ~21.3 kg.
Trial involved adults with obesity/overweight and weight-related comorbidities (no type 2 diabetes); side effects were mostly mild/moderate gastrointestinal symptoms and fatigue, with improved tolerability via dose escalation.
Eli Lilly plans to initiate pivotal phase 3 trials and is exploring combining eloralintide with its GLP-1 therapy tirzepatide to enhance treatment options.
Amylin receptor agonist profile may offer lower lean muscle loss relative to fat mass compared to GLP-1 drugs, potentially improving body composition outcomes.

Nov 7, 2025, 12:06 AM

Bloomberg

BioAge Labs reports third quarter 2025 results and clinical updates

LLY

Earnings

New Projects/Investments

Third quarter 2025 collaboration revenue was $2.1 M, research and development expenses $18.5 M, general and administrative expenses $6.7 M, and net loss $20.2 M ( $0.56 per share ).
Cash, cash equivalents, and marketable securities totaled $295.9 M as of September 30, 2025, providing runway through 2029 under current plans.
First participant dosed in the Phase 1 trial of BGE-102, an oral CNS-penetrant NLRP3 inhibitor, with initial single ascending dose data expected by year-end 2025.
Oral and parenteral APJ agonist programs advanced toward IND submissions in 2026.
Ongoing research collaborations with Novartis and Lilly ExploR&D to identify and develop novel metabolic aging targets.

Nov 6, 2025, 9:45 PM

Press Release

Lilly announces executive committee expansions and leadership role enhancements

LLY

Management Change

Hiring

Carole Ho, M.D. joins as executive vice president and president, Lilly Neuroscience, and becomes an Executive Committee member, bringing over 20 years in neurology and rare disease development.
Adrienne Brown is promoted to executive vice president and president, Lilly Immunology, joining the Executive Committee after 20+ years with Lilly, including leading the U.S. launch of Mounjaro.
Daniel Skovronsky, M.D., Ph.D., expands his role as chief scientific and product officer and president of Lilly Research Laboratories, overseeing R&D and global product strategy.
Jacob Van Naarden assumes additional oversight of corporate business development while continuing as executive vice president and president, Lilly Oncology.
These changes are designed to accelerate Lilly's pipeline, generate new portfolio opportunities, and strengthen patient access to medicines, according to CEO David A. Ricks.

Nov 6, 2025, 9:05 PM

Press Release

Lilly expands government-backed access to obesity treatments

LLY

New Projects/Investments

Product Launch

Agreement to cap Medicare out-of-pocket cost at $50/month for Zepbound and orforglipron starting April 1, 2026, with optional Medicaid expansion by states.
Self-pay access via LillyDirect: Zepbound pen priced $299–$449 per dose (refills capped at $449) and orforglipron priced $149–$399.
Emgality, Trulicity and Mounjaro added to LillyDirect with 50–60% discounts; insulin remains capped at $35/month for all patients.
Commitment of >$50 billion to U.S. manufacturing investments and securing three years of tariff relief.

Nov 6, 2025, 6:54 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for LLY.

No recent filings or transcripts found for LLY.